TCT-248 Absorb bioresorbable vascular scaffold in patients with or without diabetes mellitus: a sub-analysis of the Italian multicenter RAI Registry ( ClinicalTrials.gov Identifier: NCT02298413)

TCT-248 Absorb bioresorbable vascular scaffold in patients with or without diabetes mellitus: a sub-analysis of the Italian multicenter RAI Registry ( ClinicalTrials.gov Identifier: NCT02298413)

Patients treated with Absorb BVS because of in-stent restenosis or bypass graft disease were excluded from current analysis. At 1-year follow-up, no differences were found between groups in terms of a device-oriented composite end-point (DOCE) (4.3% vs. 6.6%; p=0.6) or its individual components (car...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B103-B103
Hauptverfasser: Mojoli, Marco, Tarantini, Giuseppe, Masiero, Giulia, Loi, Bruno, Cortese, Bernardo, Ielasi, Alfonso, Varricchio, Attilio, Moretti, Luciano, Misuraca, Leonardo, Pasquetto, Giampaolo, Calabro', Paolo, Corrado, Donatella, Steffenino, Giuseppe
Format: Artikel
Sprache:eng
Schlagworte:
Biocompatibility
Biomedical materials
Cardiology
Diabetes
Diabetes mellitus
Patients
Stents
Surgical implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients treated with Absorb BVS because of in-stent restenosis or bypass graft disease were excluded from current analysis. At 1-year follow-up, no differences were found between groups in terms of a device-oriented composite end-point (DOCE) (4.3% vs. 6.6%; p=0.6) or its individual components (cardiac death, target-vessel myocardial infarction and ischemia-driven TLR).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.321